Researchers funded by the National Institute of Mental Health have found that an inexpensive program that trains primary care providers to work with patients and mental health specialists to diagnose and properly treat depression can reduce the time that participating patients spend clinically depressed. Over a two-year period, the program reduced the duration of participating patients' depression by well over a month. The training program cost less than $500 per depressed patient and increased the time that the depressed patients spent employed during that two-year period by about four work weeks.
Researchers funded by the National Institute of Mental Health have found that an inexpensive program that trains primary care providers to work with patients and mental health specialists to diagnose and properly treat depression can reduce the time that participating patients spend clinically depressed. Over a two-year period, the program reduced the duration of participating patients' depression by well over a month. The training program cost less than $500 per depressed patient and increased the time that the depressed patients spent employed during that two-year period by about four work weeks.
"This study shows that reducing the suffering that depression brings to nearly 19 million Americans a year, in a cost-effective way, is an achievable goal," said NIMH Director Steven E. Hyman.
Forty-six primary care clinics in six managed care organizations participated in the study. The clinics were located in geographically and socioeconomically diverse communities across the United States. The research team randomly assigned the clinics to conduct depression care as they usually would or to participate in one of two interventions, which offered training to clinicians, patients and nurses, and resources to obtain effective medication or psychotherapy for depression. Researchers identified 1,356 patients with current depression through screening 27,332 consecutive patients. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.